Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 285

1.

Clinical evaluation of an individualized risk prediction tool for men on active surveillance for prostate cancer.

Huntley JH, Coley RY, Carter HB, Radhakrishnan A, Krakow M, Pollack CE.

Urology. 2018 Aug 29. pii: S0090-4295(18)30903-8. doi: 10.1016/j.urology.2018.08.021. [Epub ahead of print]

PMID:
30171924
2.

Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.

Druskin SC, Mamawala M, Tosoian JJ, Epstein JI, Pavlovich CP, Carter HB, Trock BJ.

J Urol. 2018 Aug 13. pii: S0022-5347(18)43703-2. doi: 10.1016/j.juro.2018.08.023. [Epub ahead of print]

PMID:
30114397
3.

Germline mutations in PPFIBP2 are associated with lethal prostate cancer.

Wu Y, Yu H, Zheng SL, Feng B, Kapron AL, Na R, Boyle JL, Shah S, Shi Z, Ewing CM, Wiley KE, Luo J, Walsh PC, Carter HB, Helfand BT, Cooney KA, Xu J, Isaacs WB.

Prostate. 2018 Jul 24. doi: 10.1002/pros.23697. [Epub ahead of print]

PMID:
30043417
4.

Stratifying Risk for Men With Low-Volume Intermediate-Risk Prostate Cancer-Reply.

Patel HD, Tosoian JJ, Carter HB, Epstein JI.

JAMA Oncol. 2018 Aug 1;4(8):1133-1134. doi: 10.1001/jamaoncol.2018.0754. No abstract available.

PMID:
29852039
5.

Prostate-Specific Antigen (PSA) Screening for Prostate Cancer: Revisiting the Evidence.

Carter HB.

JAMA. 2018 May 8;319(18):1866-1868. doi: 10.1001/jama.2018.4914. No abstract available.

PMID:
29800999
6.

Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.

Patel HD, Gupta M, Tosoian JJ, Carter HB, Partin AW, Epstein JI.

J Urol. 2018 Apr 17. pii: S0022-5347(18)42985-0. doi: 10.1016/j.juro.2018.04.058. [Epub ahead of print]

PMID:
29673946
7.

A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.

Wu Y, Yu H, Zheng SL, Na R, Mamawala M, Landis T, Wiley K, Petkewicz J, Shah S, Shi Z, Novakovic K, McGuire M, Brendler CB, Ding Q, Helfand BT, Carter HB, Cooney KA, Isaacs WB, Xu J.

Prostate. 2018 Jun;78(8):607-615. doi: 10.1002/pros.23505. Epub 2018 Mar 9.

PMID:
29520813
8.

Risk Stratification in Active Surveillance: A Dynamic, Ever-Evolving Practice.

Tosoian JJ, Carter HB.

Eur Urol. 2018 May;73(5):713-714. doi: 10.1016/j.eururo.2018.02.006. Epub 2018 Feb 17. No abstract available.

PMID:
29458984
9.

Targeted antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy during active surveillance: Effect on hospitalization.

Cheung C, Patel HD, Landis P, Carter HB, Han M.

Urol Oncol. 2018 Apr;36(4):158.e7-158.e12. doi: 10.1016/j.urolonc.2017.12.005. Epub 2017 Dec 26.

PMID:
29288004
10.

Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.

Druskin SC, Tosoian JJ, Young A, Collica S, Srivastava A, Ghabili K, Macura KJ, Carter HB, Partin AW, Sokoll LJ, Ross AE, Pavlovich CP.

BJU Int. 2018 Apr;121(4):619-626. doi: 10.1111/bju.14098. Epub 2018 Jan 9.

PMID:
29232037
11.

Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.

Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R.

Ann Intern Med. 2018 Jan 2;168(1):1-9. doi: 10.7326/M17-0548. Epub 2017 Nov 28.

12.

Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.

Tosoian JJ, Mamawala M, Patel HD, Alam R, Epstein JI, Ross AE, Carter HB.

J Urol. 2018 Apr;199(4):954-960. doi: 10.1016/j.juro.2017.10.029. Epub 2017 Oct 24. Erratum in: J Urol. 2018 May 8;:.

PMID:
29074222
13.
14.

Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Con.

Tosoian JJ, Carter HB.

J Urol. 2017 Nov;198(5):997-999. doi: 10.1016/j.juro.2017.08.088. Epub 2017 Sep 22. No abstract available.

PMID:
28947084
15.

Informational needs during active surveillance for prostate cancer: A qualitative study.

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Ciprut S, Sedlander E.

Patient Educ Couns. 2018 Feb;101(2):241-247. doi: 10.1016/j.pec.2017.08.022. Epub 2017 Sep 1.

PMID:
28886974
16.

Managing high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands on prostate biopsy.

Tosoian JJ, Alam R, Ball MW, Carter HB, Epstein JI.

Nat Rev Urol. 2018 Jan;15(1):55-66. doi: 10.1038/nrurol.2017.134. Epub 2017 Aug 31. Review.

PMID:
28858331
17.

Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.

Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS.

Eur Urol. 2017 Dec;72(6):899-907. doi: 10.1016/j.eururo.2017.07.018. Epub 2017 Aug 23.

PMID:
28844371
18.

Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group.

Patel HD, Tosoian JJ, Carter HB, Epstein JI.

JAMA Oncol. 2018 Jan 1;4(1):89-92. doi: 10.1001/jamaoncol.2017.1879.

19.

Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance.

Tosoian JJ, Patel HD, Mamawala M, Landis P, Wolf S, Elliott DJ, Epstein JI, Carter HB, Ross AE, Sokoll LJ, Pavlovich CP.

Prostate Cancer Prostatic Dis. 2017 Sep;20(3):339-342. doi: 10.1038/pcan.2017.16. Epub 2017 Apr 18.

20.

Comparison of Biochemical Recurrence-Free Survival after Radical Prostatectomy Triggered by Grade Reclassification during Active Surveillance and in Men Newly Diagnosed with Similar Grade Disease.

Diniz CP, Landis P, Carter HB, Epstein JI, Mamawala M.

J Urol. 2017 Sep;198(3):608-613. doi: 10.1016/j.juro.2017.03.122. Epub 2017 Mar 24.

PMID:
28347771

Supplemental Content

Loading ...
Support Center